|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/12/18 Relmada Therapeutics, Inc. 10-Q 12/31/17 62:2.9M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 236K
2: EX-4.1 Form of Convertible Promissory Note HTML 37K
3: EX-4.2 Form of Warrant to Purchase Common Stock HTML 53K
4: EX-10.1 Form of Note and Warrant Purchase Agreement HTML 35K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
15: R1 Document and Entity Information HTML 38K
16: R2 Consolidated Balance Sheets (Unaudited) HTML 86K
17: R3 Consolidated Balance Sheets (Unaudited) HTML 39K
(Parenthetical)
18: R4 Consolidated Statements of Operations (Unaudited) HTML 51K
19: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 90K
20: R6 Business HTML 22K
21: R7 Summary of Significant Accounting Policies HTML 60K
22: R8 Prepaid Expenses HTML 23K
23: R9 Fixed Assets HTML 24K
24: R10 Accrued Expenses HTML 24K
25: R11 Note Payable HTML 21K
26: R12 Derivative Liabilities HTML 31K
27: R13 Promissory Notes Payable HTML 20K
28: R14 Stockholders' Equity HTML 56K
29: R15 Related Party Transactions HTML 23K
30: R16 Commitments and Contingencies HTML 37K
31: R17 Subsequent Events HTML 22K
32: R18 Summary of Significant Accounting Policies HTML 101K
(Policies)
33: R19 Summary of Significant Accounting Policies HTML 47K
(Tables)
34: R20 Prepaid Expenses (Tables) HTML 23K
35: R21 Fixed Assets (Tables) HTML 24K
36: R22 Accrued Expenses (Tables) HTML 23K
37: R23 Derivative Liabilities (Tables) HTML 30K
38: R24 Stockholders' Equity (Tables) HTML 53K
39: R25 Commitments and Contingencies (Tables) HTML 27K
40: R26 Summary of Significant Accounting Policies HTML 35K
(Details)
41: R27 Summary of Significant Accounting Policies HTML 26K
(Details 1)
42: R28 Summary of Significant Accounting Policies HTML 26K
(Details 2)
43: R29 Summary of Significant Accounting Policies HTML 25K
(Details Textual)
44: R30 Prepaid Expenses (Details) HTML 32K
45: R31 Fixed Assets (Details) HTML 28K
46: R32 Accrued Expenses (Details) HTML 30K
47: R33 Notes Payable (Details) HTML 25K
48: R34 Derivative Liabilities (Details) HTML 37K
49: R35 Promissory Notes Payable (Details) HTML 37K
50: R36 Stockholders' Equity (Details) HTML 54K
51: R37 Stockholders' Equity (Details 1) HTML 31K
52: R38 Stockholders' Equity (Details 2) HTML 40K
53: R39 Stockholders' Equity (Details 3) HTML 33K
54: R40 Stockholders' Equity (Details 4) HTML 25K
55: R41 Stockholders' Equity (Details Textual) HTML 133K
56: R42 Related Party Transactions (Details) HTML 25K
57: R43 Commitments and Contingencies (Details) HTML 35K
58: R44 Commitments and Contingencies (Details Textual) HTML 35K
59: R45 Subsequent Events (Details) HTML 23K
61: XML IDEA XML File -- Filing Summary XML 101K
60: EXCEL IDEA Workbook of Financial Reports XLSX 57K
9: EX-101.INS XBRL Instance -- rlmd-20171231 XML 696K
11: EX-101.CAL XBRL Calculations -- rlmd-20171231_cal XML 115K
12: EX-101.DEF XBRL Definitions -- rlmd-20171231_def XML 400K
13: EX-101.LAB XBRL Labels -- rlmd-20171231_lab XML 672K
14: EX-101.PRE XBRL Presentations -- rlmd-20171231_pre XML 536K
10: EX-101.SCH XBRL Schema -- rlmd-20171231 XSD 112K
62: ZIP XBRL Zipped Folder -- 0001213900-18-001597-xbrl Zip 88K
Exhibit 10.1
RELMADA THERAPEUTICS, INC.
NOTE AND WARRANT PURCHASE AGREEMENT
THIS NOTE AND WARRANT PURCHASE AGREEMENT (the “Purchase Agreement”), dated this __ day of __________ 2017, is by and between ___________, (the “Buyer”), and RELMADA, THERAPEUTICS, INC., a Nevada corporation (the “Company”).
WHEREAS, the Buyer wishes to purchase from the Company and the Company wishes to sell to the Buyer, upon the terms and subject to the conditions of this Purchase Agreement, a convertible promissory note of the Company, in the principal amount of $.
NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1. Sale and Issuance of Note and Warrant. Upon the terms and subject to the conditions of this Purchase Agreement, the Buyer agrees to purchase from the Company, and the Company agrees to sell and issue to the Buyer, a convertible subordinated promissory note, in the form attached hereto as Exhibit A (the “Note”), in the principal amount of $____________(the “Principal Sum”), subject to the terms and conditions of the Note. In order to induce the Buyer to purchase the Note, the Company will deliver a warrant, in the form attached hereto as Exhibit B (the “Warrant”), to the Buyer to purchase, subject to the terms and conditions of the Warrant, in whole or in part, up to that number of fully paid, validly issued and nonassessable shares of Company’s common stock (the “Common Stock”). Each Warrant will entitle such Investor to purchase up to that number of shares of Common Stock equal to (a) fifty percent (50%) of the Principal Sum purchased by such Investor divided by (b) $0.75. The exercise price per share for the Warrant shall be $1.50.
2. Representations and Warranties of the Company. By executing this Purchase Agreement, the Company makes the following representations and, warranties to the Buyer, with the intent and understanding that the Buyer will rely thereon:
2.1 Organization of the Company; Authorization; Good Standing. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to own and lease its property, to carry on its business as presently conducted and as proposed to be conducted (as previously disclosed to the Buyer) and to execute and deliver, and to perform all of its obligations under, this Purchase Agreement, the Note and the Warrant (collectively, the “Company Documents”).
2.2 Enforceability. The creation and issue of the Note and the execution and delivery by the Company of the Company Documents and the consummation of the transactions contemplated thereby have been duly authorized by all requisite corporate action on the part of the Company, and the Company Documents have been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms.
2.3 Complete and Accurate Information. All information provided by the Company in whatever form in connection with the transactions contemplated by the Company Documents are complete and accurate and provide a true and fair view of the financial position of the Company.
C:
3. Representations and Warranties of the Buyer. By executing this Purchase Agreement, the Buyer makes the following representations and warranties to the Company, with the intent and understanding that the Company will rely thereon:
3.1 Investment Representations. The Buyer has knowledge and experience in financial and business matters sufficient to enable him to evaluate the merits and risks of an investment in the Note, the shares of the Company’s Common stock issuable upon conversion of the Note (the “Shares”) and the Company. The Buyer has assets sufficient to enable him to bear the economic risk of the Buyer’s investment in the Note. The Buyer is acquiring the Note for investment purposes only, for his, her or its own account, and not with a present view to, or for sale in connection with, any distribution thereof. The Buyer understands that the Note and the Shares have not been registered under the Securities Act by reason of their issuance in a transaction exempt from the registration requirements of the Securities Act pursuant to the exemption provided in Section 4(2) thereof, that the Note and the Shares have not been registered under applicable state securities laws by reason of their issuance in a transaction exempt from such registration requirements, and that the Note and the Shares may not be sold or otherwise disposed of unless registered under the Securities Act and applicable state securities laws (the Company being under no obligation to register such Note or the Shares) or exempted from registration. The Buyer further acknowledges that the Note and the Shares are subject to the restrictions on transfers set forth in the Company Documents, and that each transferee of the Note or the Shares as a condition to such transfer may be required to agree in writing to be bound by such restrictions.
3.2 Buyer’s Acknowledgment as to Information. The Buyer or representatives of the Buyer have received from the Company such information (including exhibits to this Purchase Agreement and of such documents referred to herein and therein as he or they have requested) with respect to the Company as the Buyer has deemed necessary and relevant in connection with the transactions contemplated by the Company Documents, and the Buyer has had the opportunity, directly or through such representatives, to ask questions of and receive answers from persons acting on behalf of the Company necessary to verify the information so obtained.
3. Legend. Each certificate evidencing the Note and the Company’s securities issuable upon conversion of the Note, and each certificate evidencing the Note and the Company’s securities issuable upon conversion of the Note held by subsequent transferees of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form:
"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER SUCH ACT, (B) A "NO ACTION" LETTER OF THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH SALE OR OFFER OR (C) SATISFACTORY ASSURANCES TO THE CORPORATION THAT REGISTRATION UNDER SUCH ACT IS NOT REQUIRED WITH RESPECT TO SUCH SALE OR OFFER."
C:
| C: 2 |
4. Miscellaneous.
4.1 Legal Fees and Expenses. Each party hereto agrees to pay its own legal fees and expenses incurred in connection with the transactions contemplated hereunder.
4.2 No Waiver. The failure of a party to insist upon strict adherence to any term of this Purchase Agreement on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Purchase Agreement. Any waiver of any term of this Purchase Agreement must be in writing.
4.3 Entire Agreement; Amendment. This Purchase Agreement and all Exhibits hereto, set forth the entire agreement of the parties with respect to the subject matter hereof and supersede all prior agreements relating thereto, written or oral. This Purchase Agreement may be amended or modified only by a written instrument executed by the Company and the Buyer.
4.4 Parties in Interest; Limitation on Assignment. This Purchase Agreement shall inure to the benefit of and be binding upon the parties and their respective permitted successors and assigns.
4.5 Counterparts. This Purchase Agreement may be executed in any number of counterparts, each of which shall be considered an original, but all of which together shall constitute one and the same instrument.
4.6 Governing Law. This Purchase Agreement shall be governed by, construed, interpreted and enforced in accordance with the laws of the State of New York as applied to contracts entered into and performed entirely within the State of New York without regard to conflicts of laws principles.
4.7 Notices. All notices, consents and other communications under this Purchase Agreement shall be in writing and shall be deemed to have been duly given when (a) delivered by hand, (b) sent by telex or telecopier (with receipt confirmed), provided that a copy is mailed by registered mail, return receipt requested, or (c) when received by the addressee, if sent by Express Mail, Federal Express or other express delivery service (receipt requested), in each case to the appropriate addresses, telex numbers and telecopier numbers set forth below (or to such other addresses, telex numbers and telecopier numbers as a party may designate as to itself by notice to the other party):
4.7.1 If to the Company:
RELMADA THERAPEUTICS, INC.
750 Third Avenue, 9th floor
Attention: Sergio Traversa, PharmD.
Chief Executive Officer
C:
| 3 |
4.7.2 If to the Buyer:
4.8 Severability. In the event that any court having jurisdiction shall determine that any provision contained in this Purchase Agreement shall be unreasonable or unenforceable in any respect, then such covenant or other provision shall be deemed limited to the extent that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such covenant or other provision wholly unenforceable, the remaining covenants and other provisions of this Purchase Agreement shall nevertheless remain in full force and effect.
4.9 Headings and Captions. The headings and captions used herein to identify sections and subsections are for convenience only and shall not be used for interpretation of any provisions herein.
4.10 Indemnity. The representations, warranties and agreements made by the Company and the Buyer herein shall survive the execution of this Purchase Agreement. The Company and the Buyer hereby agree to indemnify and hold harmless the other party from and against any and all loss, liability, claim, damage and expense (including, without limitation, attorneys’ fees and disbursements) suffered or incurred as a result of a misrepresentation or breach of any warranty or agreement made by the defaulting party in this Purchase Agreement.
[Signature Page Follows]
C:
| 4 |
IN WITNESS WHEREOF, each of the parties has caused this Purchase Agreement to be executed on its behalf with the intent to be legally bound as of the day and year first above written.
| RELMADA THERAPEUTICS, INC. | ||||
| By: | ||||
| Name: | Sergio Traversa, PharmD | |||
| Title: | Chief Executive Officer | |||
| BUYER: | ||||
| Name: | ||||
| Title: | ||||
C:
EXHIBIT A
FORM OF CONVERTIBLE PROMISSORY NOTE
(see attached)
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/19/24 Relmada Therapeutics, Inc. 10-K 12/31/23 56:4.3M EdgarAgents LLC/FA 3/23/23 Relmada Therapeutics, Inc. 10-K 12/31/22 55:4.4M EdgarAgents LLC/FA 3/25/22 Relmada Therapeutics, Inc. 10-K 12/31/21 61:4.3M EdgarAgents LLC/FA 3/24/21 Relmada Therapeutics, Inc. 10-K 12/31/20 65:4.7M EdgarAgents LLC/FA |